<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996306</url>
  </required_header>
  <id_info>
    <org_study_id>AXEPT</org_study_id>
    <secondary_id>UMIN000012263</secondary_id>
    <nct_id>NCT01996306</nct_id>
  </id_info>
  <brief_title>A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC</brief_title>
  <acronym>AXEPT</acronym>
  <official_title>A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epidemiological and Clinical Research Information Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the non-inferiority of overall survival
      XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as
      Second-line therapy in Patient with Metastatic Colorectal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival
      (PFS), Time to treatment failure (TTF), Overall response rate (ORR),Disease Control Rate
      (DCR), Relative dose intensity, Safety, and Correlation between UGT1A1 genotype and Safety.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to the earlier of the date of confirmed progression, death from any cause, or discontinuation of protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Assessed at 6, 12 week and thereafter every 8 weeks</time_frame>
    <description>Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Assessed at 6, 12 week and thereafter every 8 weeks</time_frame>
    <description>Proportion of best overall response of CR, PR, or SD assessed by the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Dose Intensity</measure>
    <time_frame>Assessed until final dosing to the last patient</time_frame>
    <description>will be calculated for each drug to evaluate treatment compliance in the all-treated population during the observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (Adverse Reactions)</measure>
    <time_frame>Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery</time_frame>
    <description>The incidence of worst-grade adverse events (toxicities) on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm in all treated patients for the following events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between UGT1A1 genotype and safety</measure>
    <time_frame>Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery</time_frame>
    <description>The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm and UGT1A1 genotype in all treated patients with a known UGT1A1 genotype profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <arm_group>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11 (Irinotecan)</intervention_name>
    <description>150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU Bolus</intervention_name>
    <description>400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU Infusion</intervention_name>
    <description>2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>l-LV (dl-LV)</intervention_name>
    <description>200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11 (Irinotecan)</intervention_name>
    <description>150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform
             appendix cancer and anal canal cancer.

          2. Age ≥20 years at the time of informed consent

          3. ECOG performance status (PS) of 0-2

          4. Written informed consent prior to study-specific screening procedures

          5. Life expectancy of at least 90 days

          6. Withdrawal from first-line chemotherapy (regardless of containing molecular-targeted
             drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive
             disease, or relapse within 180 days after the last dose of adjuvant chemotherapy.

          7. Adequate organ function according to following laboratory values obtained within 14
             days before enrolment (excluding patients who received blood transfusions or
             hematopoietic growth factors within 14 days before the laboratory test) Neutrophil
             count: ≥1500/mm3 Platelet count: ≥10.0 x 104/mm3 Hemoglobin: ≥9.0 g/dL Total
             bilirubin: ≤1.5 mg/dL AST, ALT: ≤100 IU/L (≤200 IU/I if liver metastases present)
             Serum creatinine: ≤1.5 mg/dL

        Exclusion Criteria:

          1. History of other malignancy with a disease-free interval &lt;5 years (other than
             curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in
             situ of the cervix, and gastroenterological cancer confirmed to be cured by endoscopic
             mucosal resection)

          2. With massive pleural effusion or ascites requiring intervention

          3. Radiological evidence of brain tumor or brain metastases

          4. Active infection including hepatitis

          5. Any of the following complication:

             i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic
             ileus) ii) Symptomatic heart disease (including unstable angina, myocardial
             infarction, and heart failure) iii) Interstitial pneumonia or pulmonary fibrosis iv)
             Uncontrolled diabetes mellitus v) Uncontrolled diarrhea (that interferes with daily
             activities despite adequate therapy)

          6. Any of the following medical history:

             Myocardial infarction: History of one episode within one year before enrollment or two
             or more lifetime episodes i) Serious hypersensitivity to any of the study drugs ii)
             History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine
             dehydrogenase (DPD) deficiency

          7. Previous treatment with irinotecan hydrochloride

          8. Current treatment with atazanavir sulfate

          9. Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days
             before enrollment

         10. Pregnant or lactating females, and males and females unwilling to use contraception

         11. Requires continuous treatment with systemic steroids

         12. Psychiatric disability that would preclude study compliance

         13. Otherwise determined by the investigator to be unsuitable for participation in the
             study

         14. Concurrent gastrointestinal perforation or history of gastrointestinal perforation
             with 1 year before enrollment

         15. History of pulmonary hemorrhage/hemoptysis ≥ Grade 2 (defined as bright red blood of
             at least 2.5mL) within 1 month prior to enrollment.

         16. History of laparotomy, thoracotomy, or intestinal resection within 28 days before
             enrollment

         17. Unhealed wound (except suture wounds from implantation of a central venous port),
             gastrointestinal ulcer, or traumatic fracture

         18. Current or recent (within 1 year) thromboembolism or cerebrovascular disease

         19. Currently receiving or requires anticoagulation therapy (&gt; 325 mg/day of aspirin)

         20. Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR ≥1.5 within
             14 days before enrollment)

         21. Uncontrolled hypertension

         22. Urine dipstick for proteinuria &gt;+2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kei Muro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aichi Cancer Center Hospital, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Won Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASAN Medical center, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Suk Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruihua Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-Sen University Cancer Center, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NPO Epidemiological and Clinical Research Information Network (ECRIN)</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXEPT</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>CPT-11</keyword>
  <keyword>XELIRI</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>2nd-line metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

